# Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

> **NCT00725231** · PHASE3 · UNKNOWN · sponsor: **University of Göttingen** · enrollment: 274 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma, Unspecified
- Angioimmunoblastic Lymphadenopathy
- Extranodal NK/T-cell Lymphoma

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT00725231
- **Lead sponsor:** University of Göttingen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 274 (ESTIMATED)
- **Last updated:** 2012-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725231, "Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00725231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*